logo

Δημοσιεύσεις

PEER REVIEWED PUBLICATIONS

  1. Argiris, C. Dardoufas, K. Aroni. “Radiotherapy induced soft tissue sarcoma. An unusual case of a dermatofibrosarcoma protuberans”Clinical Oncology 1995;7:59-61
  2. Argiris, G. Plataniotis, E. Michalopoulos, J. Kouvaris, C. Papavasiliou. “Palliative treatment for non-small cell lung cancer with a short course of radiotherapy”Hellenic Radiology 1995; 26:49-53 [in Greek language, abstract in English]
  3. Argiris, T. Maris, G. Papavasiliou, A. Gouliamos, C. Papavasiliou. “Radiotherapy effects on vertebral bone marrow: easily recognizable changes in T2 relaxation times”Magnetic Resonance Imaging 1996;14:633-38
  4. Argiris, T. Maris, L. Vlahos. “T2 relaxation times of irradiated vertebral bone marrow in patients with seminoma ”Magnetic Resonance Imaging 1997;15:335-40
  5. Argiris, G. Longo, R. Gorlick, W. Tong, P. Steinherz, J.R. Bertino. “Increased methotrexate polyglutamylation in a cute megakaryocyticleukemia (M7) compared too theracutemyelocyticleukemia subtypes ”Leukemia 1997;11:886-9
  6. Argiris. Splenic and renal infarctions complicating atrial fibrillation” The Mount Sinai Journal of Medicine 1997;64:342-9
  7. Argiris, J. Rademaker, M. Mahmud. “Dislodgement of an inferior vena cava filter to the internal jugular vein”Intensive Care Medicine 1997;23:1186-7
  8. Argiris, U. Mathur, I. Wilets, D. Mildvan. “Abnormalities of serum amylase and lipase in HIV positive patients”American Journal of Gastroenterology 1999;94:1248-52
  9. D. Gould, A. Argiris. “Unilateral breast edema as a manifestation of congestive heart failure”The Journal of Internal Medicine 1998;243:328-9
  10. Argiris, N. Maun, N. Berliner. “Mycobacterium avium intracellulare inclusions mimicking Gaucher cells” New England Journal of Medicine 1999;340:1372
  11. A.A. Adjei, A. Argiris, J.R. Murren. “Docetaxel and irinotecan, alone and in combination, in the treatment of non-small cell lung cancer”Seminars in Oncology 1999;26 (suppl 16):32-40
  12. Argiris, S. Seropian, D.L. Cooper. “High-dose BEAM chemotherapy with autologous peripheral blood progenitor-cell transplantation for patients with primary refractory or relapsed Hodgkin’s disease”Annals of Oncology 2000;11:665-72
  13. Argiris, P. Heald, T. Kuzel, F.M. Foss, S. DiStasio, D.L. Cooper, S. Arbuck, J.R. Murren. “Phase II trial of 9-AC in cutaneous T-cell lymphoma”Investigational New Drugs 2001;19;321-26
  14. Argiris, J. R. Murren. “Advances in chemotherapy for small cell lung cancer: single-agent activity of newer agents”Cancer Journal 2001;7:228-235
  15. Argiris, J.R. Murren. “Staging and clinical prognostic factors in small cell lung cancer”Cancer Journal 2001;7:437-47
  16. Argiris, “Update on chemoradiotherapy for head and neck cancer” Current Opinion in Oncology 2002;14:323-9
  17. Argiris, S.M. Smith, K. Stenson, B.B. Mittal, H.J. Pelzer, M.S.Kies, D.J. Haraf, E.E.Vokes. “Chemoradiotherapy forN2 or N3 squamous cell carcinoma of the head and neck from an occult primary”Annals of Oncology 2003;14:1306-11
  18. I.M. Modlin, M. Kidd, T. Hinoue, K.D. Lye, J. Murren, A. Argiris. “Molecular strategies and 111in-labelled somatostatin analogues in defining the management of neuroendocrine tumour disease: a new paradigm for surgical management” Surgeon 2003;1:137-43
  19. E. Bleichart, A. Argiris, R. Rich, K. Blum, A. McKeon, H. Tara, D. Zelterman, B. Burtness, M.J. Davies, J.R. Murren. “Phase I dose escalation trial of weekly docetaxel plus irinotecan in patients with advanced cancer”Cancer Biology and Therapy 2002;1:646-51
  20. M. Simon, A. Argiris, J.R. Murren “Progressinsmallcelllungcancer”Critical Reviews in Oncology/Hematology 2004;49:119-33
  21. Argiris, A. Mellott, S. Spies. “PET scan assessment of chemotherapy response in metastatic paraganglioma” American Journal of Clinical Oncology 2003;26:563-6
  22. Argiris, J. Dutra, P. Tseke, K. Haines. “Esthesioneuroblastoma-the NorthwesternUniversity experience” The Laryngoscope 2003;113:155-160
  23. Argiris,C. Wang, S. Whalen, M. Digiovanna. “Synergistic interactions between tamoxifen and trastuzumab (Herceptin)”Clinical Cancer Research2004;10:1409-20
  24. Argiris, D. Haraf, M. Kies, E. Vokes. “Intensive chemoradiotherapy with 5-FU and hydroxyurea-based regimens for head and neck cancer: reversing a pattern of failure”The Oncologist 2003;8:350-60
  25. Mittal, B.R. Pauloski, D.J. Haraf, H.J. Pelzer, A. Argiris, E.E.Vokes, A Rademaker, J.A. Logemann. Swallowing dysfunction - preventative and rehabilitation strategies in patients with head and neck cancers treated with surgery, radiotherapy, and chemotherapy: a critical review” Int J Radiat Oncol Biol Phys 2003;57 (5):1219-30
  26. Argiris, M. Liptay, M. LaCombe, M. Marymont, M.S. Kies, S. Sundaresan, G.Masters. “A phase I/II trial of induction chemotherapy with carboplatin and gemcitabine followed by concurrent vinorelbine and paclitaxel with chest irradiation in patients with stage III non-small cell lung cancer”Lung Cancer 2004;45:243-53
  27. Argiris, Y. Li, C. Langer, B. Murphy, A. Forastiere. “Outcome of elderly patients with recurrent or metastatic head and neck cancer treated with cisplatin-based chemotherapy”J Clin Oncology 2004;22:262-8
  28. Argiris , B.E. Brockstein, D.J. Haraf, K.M. Stenson, B.B. Mittal, M.S. Kies, F.R. Rosen, B. Jovanovic, E.E.Vokes.“Competing causes of death and second primary tumors in patients with locoregionally advanced head and neck cancer treated with hemoradiotherapy”Clinical Cancer Research 2004;10:1956-62
  29. Haraf, K. Stenson, F.R. Rosen, A. Argiris, B.B. Mittal, M.E. Witt, B.E. Brockstein, M.A. List, L. Portugal, H. Pelzer, R.R. Weichselbaum, E.E.Vokes “Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer” Clinical Cancer Research 2003;9:5936-43
  30. Argiris, N. Mittal. “Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer” Lung Cancer 2004;43:317-22
  31. J. Patel, B. Pasche,A. Argiris.“Targeting non-small cell lung cancer with oral epidermal growth factor tyrosine kinase inhibitors: where do we stand, where do we go”Critical Reviews in Oncology/Hematology 2004;50:175-86
  32. Argiris, K.M. Stenson, B.E. Brockstein, B.B. Mittal, H. Pelzer, M.S. Kies, P. Jayaram, L. Portugal, B.L. Wenig, F.R. Rosen, D.J. Haraf, E.E. Vokes.“Neck dissection in the combined modality therapy of patients with locoregionally advanced head and neck cancer”Head and Neck 2004;26:447-55
  33. Argiris, P. Jayaram, D. Pichardo. “Revisiting induction chemotherapy for head and neck cancer”Oncology (WillistonPark) 2005;19(7):932-4, 939; discussion 939-45
  34. Argiris, Y. Li, A. Forastiere. “Prognostic factors and long-term survivorship in patients with recurrent or metastatic head and neck cancer: an analysis of two Eastern Cooperative Oncology Group randomized trials”Cancer 2004;101:2222-9
  35. J. Patel, M. Blum, A. Argiris. “Induction chemotherapy for resectable non-small cell lung cancer”Oncology (WillistonPark) 2004;18:1591-602
  36. M.T.Milano, D.J. Haraf, K.M. Stenson, M.E. Witt, C. Eng, B.B. Mittal, A. Argiris, H. Pelzer, M.F. Kozloff, E.E. Vokes.”Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, gemcitabine and twice-daily radiation in patients with poor-prognosis cancer of the head and neck”Clinical Cancer Research 2004;10:4922-32
  37. V. Kut, J. Patel, A. Argiris.“Pemetrexed: a novel antifolate agent enters clinical practice”Expert Review of Anticancer Therapy 2004;4:511-22
  38. Argiris, J. Schiller “Can current treatments for advanced non-small cell lung cancer be improved ?” Editorial. JAMA 2004;292:499-500
  39. Argiris, V. Kut, L. Luong, M. Avram. “Phase I and pharmacokinetic study of docetaxel, irinotecan, and celecoxib in patients with advanced non-small cell lung cancer” Investigational New Drugs 2006;24:203-12
  40. Μ.Τ. Milano, Ε.Ε. Vokes, J.K. Salama, K.M. Stenson, J. Kao, M.E. Witt, B.B. Mittal, A. Argiris, R.R. Weichselbaum, D.J. Haraf. “Twice-daily reirradiation for recurrent and second primary head-and-neck cancer with gemcitabine, paclitaxel, and 5-fluorouracil chemotherapy” Int J Radiat Oncol Biol Phys 2005;61:1096-106
  41. Argiris, C.X. Wang, D.C. Koay, M.P. Digiovanna. “Growth and molecular interactions between tamoxifen and trastuzumab”Clinical Cancer Research 2005 11:3597; author reply 3597-9
  42. Argiris. “Induction chemotherapy for head and neck cancer: will history repeat itself ?” J Natl Compr Canc Netw 2005 May;3(3):393-403
  43. A.Argiris, T. Hensing, A. Yeldandi, S. Patel, A. Raji, C. Sturgis, G. Masters, W. Gooding, M. Pins, J. Kolesar. “Combined analysis of molecular and clinical predictors of gefitinib activity in advanced non-small cell lung cancer: EGFR mutations do not tell the whole story” Journal of Thoracic Oncology 2006;1:52-60
  44. G. Masters, A. Argiris, E.A. Hahn, J.T. Beck, P.G. Rausch, Z. Ye, M.J. Monberg, L.P. Bloss, R.E. Curiel, C.K. Obasaju.“A Randomized Phase II Trial Using Two Different Treatment Schedules of Gemcitabine and Carboplatin in Patients with Advanced Non-Small Cell Lung Cancer”Journal of Thoracic Oncology 2006;1:19-24
  45. K.M. Stenson, D. Huo, E. Blair, E.E. Cohen, A. Argiris, D.J. Haraf,E.E. Vokes.“Planned post-chemoradiation neck dissection: significance of radiation dose”Laryngoscope 2006;116:33-6
  46. Gidron, M. Quadrini, N. Dimov, A. Argiris “Malignant thymoma associated with fatal polymyositis and myocarditis”Am J Clinical Oncology 2006;29:213-4
  47. H. Wanebo, A. Argiris, E. Bergsland, S. Agarwala, H. Rugo. “Targeting Growth Factors and Angiogenesis; Using Small Molecules in Malignancy” Cancer Metastasis Reviews 2006;279-91
  48. J. Gilbert, A. Argiris. “Emerging molecular targeted therapies in head and neck cancer”Clinical Advances in Hematology-Oncology 2006;4:611-9
  49. Argiris, E. Cohen, T. Karrison, B. Esparaz, A. Mauer, R. Ansari, S. Wong, Y. Lu , M. Pins, J. Dancey, E. Vokes. “A phase II trial of perisosine, an oral alkylphospolipid, in recurrent or metastatic head and neck cancer” Cancer Biology and Therapy 2006;5:766-70
  50. Argiris. “Cetuximab prolongs survival when added to radiotherapy for locally advanced head and neck cancer” Editorial comment. Abstracts in Hematology and Oncology 2006;9(2):10-12
  51. V. Kut, W. Spies, S. Spies, W. Gooding, A. Argiris. “Staging and monitoring of small cell lung cancer using using [F-18]fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET)”Am J Clinical Oncology 2007;30(1):45-50
  52. M. Karamouzis, J. Grandis, A. Argiris. “Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas”JAMA 2007;298:70-82
  53. S. Agarwala, E. Cano, D.E. Heron, J. Johnson, E. Myers, V. Sandulache, S. Bahri, R. Ferris, Y. Wang, A. Argiris. “Long-term outcomes with concurrent carboplatin, paclitaxel, and radiation therapy in locally advanced, inoperable head and neck cancer”Annals of Oncology 2007;18:1224-9
  54. S. Ramalingam, R.A. Parise, R.K. Ramanathan, T.F. Lagattuta, L. Musguire, R. Stoller, D. Potter, A. Argiris, J. Zwiebel, M.J.Egorin, C.P. Belani.“Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies” Clinical Cancer Research 2007; 13:3605-10
  55. J.V. Nayak, R. Walvekar, N. Daamen, R.S. Andrade, S.Y. Lai, A. Argiris, R.P. Smith, D.E. Heron, R.L. Ferris, J.T. Johnson, B.F. Branstetter. “Deferring planned neck dissection following chemoradiation for stage IV head and neck cancer: the utility of PET-CT”Laryngoscope 2007;117:2129-34
  56. Argiris, M. Karamouzis, D. Raben, R. Ferris. “Head and neck cancer” Lancet 2008;371:1695-709
  57. S. Yount, M. List, H. Du, K. Yost, R. Bode, B. Brockstein, A. Argiris, E. Vokes, E. Cohen, A. Mauer, B. Campbell, V. Valenzuela, J. George, R. Egan, J. Chen, D. Meddis, D. Cella. “A randomized validation study comparing embedded versus extracted FACT Head and Neck Symptom Index scores” Quality of Life Research 2007;16:1615-26
  58. Argiris, M.V. Karamouzis, J. Johnson, D.E. Heron, E. Myers, D. Eibling, E. Cano, S. Urba, J. Gluckman, J. Grandis, Y. Wang, S. Agarwala.“Long-term results of a phase III randomized trial of postoperative radiotherapy with or without carboplatin in patients with high-risk head and neck cancer”Laryngoscope 2008;118:444-9
  59. B.A. Burtness, J. Manola,R. Axelrod,A. Argiris,A.A. Forastiere. “A Randomized Phase II Study of Ixabepilone (BMS-247550) Given Daily x 5 Days Every 3 Weeks or Weekly in Patients with Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck: An Eastern Cooperative Oncology Group Study”Annals of Oncology 2008;19:977-83
  60. M.V. Karamouzis, A. Argiris, J.R. Grandis. “Clinical applications of gene therapy for head and neck cancer”Current Gene Therapy 2007;7:446-57
  61. Argiris, S.S. Agarwala, M.V. Karamouzis, L.A. Burmeister, S.E. Carty. “A phase II trial of doxorubicin and interferon alpha 2b in advanced, non-medullary thyroid cancer” Investigational New Drugs 2007;26:183-8
  62. M. Fidler, A. Argiris, J.D. Patel, D. Johnson, A. Sandler, V. Villaflor, J. Coon, L. Buckingham, K. Kaiser,S. Basu, P. Bonomi “The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib”Clinical Cancer Research 2008;14:2088-94
  63. N.J. Nonzee, N.A. Dandade, C.C. Tigue, T. Markossian, J.M. McKoy, M. Alkhatib, M. Agulnik, J.D. Patel, R.C. Kern, J.C.F. Dutra, H. Munshi, A. Argiris, E.A. Calhoun,C.L. Bennett. “Evaluating the supportive care costs of severe radiochemotherapy-induced mucositis and pharyngitis: Results from a Northwestern University Costs of Cancer Program pilot study with head and neck and non-small cell lung cancer patients who received care at a county hospital, a VA hospital, or a comprehensive cancer care center”Cancer 2008;113(6): 1446-1452
  64. J.K. Salama, K.M. Stenson, E.O. Kistner, B. Mittal, A. Argiris, M. E. Witt, F. Rosen, B.E. Brockstein, E.E.W. Cohen, D.J. Haraf, E.E. Vokes. “Induction Chemotherapy and Concurrent Chemoradiotherapy for Locoregionally Advanced Head and Neck Cancer: A Multi-Institutional Phase II Trial Investigating Three Radiotherapy Dose Levels”Annals of Oncology 2008; 19 (10): 1787-1794
  65. S.Y. Lai, P. Koppikar, S.M. Thomas, E.E. Childs, A.M. Egloff, R.R. Seethala, B.F. Branstetter, W.E. Gooding, A. Muthukrishnan, J.M. Mountz, V.W.Y. Lui, D.M. Shin, S. S. Agarwala, R. Johnson, L.A. Couture, E.N. Myers, J.T. Johnson, G. Mills, A. Argiris, J.R. Grandis. “Intratumoral Epidermal Growth Factor Receptor Antisense DNA Therapy in Head and Neck cancer: First Human Application and Potential Antitumor Mechanisms”JClin Oncology 2009;27: 1235-1242
  66. J. Grandis, A. Argiris. “Targeting angiogenesis from premalignancy to metastases”Cancer Prev Res (PhilaPa) 2009;2:291-4
  67. Argiris, A. Buchanan, B. Brockstein, J. Kolesar, M. Ghebremichael, M. Pins, K. Hahn, R. Axelrod,A. Forastiere. “Docetaxel and irinotecan in recurrent or metastatic head and neck cancer: a phase II trial of the Eastern Cooperative Oncology Group”Cancer 2009;115:4504-13
  68. D.E. Heron, R.L. Ferris, M. Karamouzis, R.S. Andrade, S. Burton, W. Gooding, B. Branstetter, J.T. Johnson, A. Argiris, J.R. Grandis, S.Y. Lai. “Stereotactic Body Radiotherapy for Recurrent Squamous Cell Carcinoma of the Head and Neck—Results of a Phase I Dose Escalation Trial” Int J Radiat Oncol Biol Phys 2009;75:1493-500
  69. A.S. Gokhale, B.T. McLaughlin, J.C. Flickinger, S. Beriwal, D.E. Heron, R.L. Ferris, J. Johnson, M.K. Gibson, A. Argiris, R.P. Smith. “Clinical and Dosimetric Factors Associated With a Prolonged Feeding Tube Requirement in Patients Treated with Chemoradiotherapy (CRT) for Head and Neck Cancers” Annals of Oncology 2010;21:145-51
  70. T.M. Feinstein, M.K. Gibson, A. Argiris. “Cetuximab-induced aseptic meningitis”Annals of Oncology 2009;20:1609-10
  71. J. Kwok, S.M. Langevin, A. Argiris, J.R. Grandis, W.E. Gooding, E. Taioli. “The impact of health insurance status on the survival of patients with head and neck cancer”Cancer 2010;116(2):476-85
  72. T. McLaughlin, A.S. Gokhale, J. Shuai, J. Diacopoulos, R. Carrau, D. E. Heron, R. Smith, M. Gibson, R. L. Ferris, J. R. Grandis, J. T. Johnson, A. Argiris. “Management of patients treated with chemoradiotherapy for head and neck cancer without prophylactic feeding tubes: the University of Pittsburgh experience”Laryngoscope 2010; 120(1):71-5
  73. S.S. Ramalingam, M. Maitland, P. Frankel, A.E. Argiris, M. Koczywas, B. Gitlitz,S. Thomas,I. Espinoza-Delgado, E.E. Vokes, D.R. Gandara, C.P. Belani. “Randomized, double-blind, placebo-controlled phase II study of carboplatin and paclitaxel with or without vorinostat, a histone deacetylase inhibitor (HDAC), for first-line therapy of advanced non-small cell lung cancer (NCI 7863)”J Clin Oncol 2010;28:56-62
  74. A, Argiris, S. Gadgeel, S. Dacic. “Subdividing non-small cell lung cancer: reflections on the past, present and future of lung cancer therapy”Oncology(Williston Park)2009;13:1147-8
  75. Chung, E. Seeley, H. Roder, J. Grigorieva, M. Tsypin, J. Roder, B. Burtness, A. Argiris, A. Forastiere, J. Gilbert, B. Murphy, R. Caprioli, D. Carbone, E. Cohen. “Detection of Tumor Epidermal Growth Factor Receptor Pathway Dependence by Serum Mass Spectrometry in Cancer Patients”Cancer Epidemiol Biomarkers Prev 201019(2):358-65
  76. V. A. Passero, B. F. Branstetter, Y. Shuai, D. E. Heron, M. K. Gibson, S. Y. Lai, S. W. Kim, R. L. Ferris, J. T. Johnson, A. Argiris. “Response assessment by combined positron emission tomography and CT scan versus RECIST in patients with locally advanced head and neck cancer treated with chemoradiotherapy”Annals of Oncology 2010;21:2278-83
  77. Tarhini, A. Kotsakis, R. Stoller, S. Dacic, W. Gooding, A. Argiris. “Phase II trial of everolimus in previously treated small cell lung cancer”Clinical Cancer Research 2010;16:5900-7
  78. Argiris, D.E. Heron, R. Smith, M.K. Gibson, S.Y. Lai, S. Kim, B.F. Branstetter, D. Posluszny, R. Seethala, W. Gooding, J.R. Grandis, J.T. Johnson, R.L. Ferris. “Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locoregionally advanced head and neck cancer”J Clin Oncol 2010;28:5294-300
  79. Argiris, M.V. Karamouzis. “Empowering induction therapy for locally advanced head and neck cancer” Annals of Oncology 2011;4:773-81
  80. A.A. Tarhini, C. Belani, J.D.Luketich, S.S. Ramalingam,A. Argiris, W. Gooding, D. Petro, K. Kane, D. Liggitt, T. ChampionSmith, X. Zhang, M.W. Epperly, J.S. Greenberger. “A Phase I Study of Concurrent Chemotherapy (Paclitaxel and Carboplatin) and Thoracic Radiotherapy with Swallowed Manganese Superoxide Dismutase (MnSOD) Plasmid Liposome (PL) Protection in Patients with Locally Advanced Stage III Non-Small Cell Lung Cancer”Human Gene Therapy 2011;22:336-42
  81. P.N. Lara, J. Longmate, B. Gitlitz, A. Argiris, S. Ramalingam, C.P. Belani, P.C. Mack, D. HM Lau, K. Reckamp, M. Koczywas, F.A. Shepherd, N. Leighl, D.R. Gandara.“Randomized Phase II Trial of Concurrent versus Sequential Bortezomib plus Docetaxel in Advanced Non-Small-Cell Lung Cancer (NSCLC): A California Cancer Consortium Trial” Clinical Lung Cancer 2011;12:33-7
  82. J.C. Rwigema, D.E. Heron, R.L. Ferris, R.S. Andrade, M.K. Gibson, Y. Yang, C. Ozhasoglu, A. Argiris, J.R. Grandis, S.A. Burton. “The Impact of Tumor Volume and Radiotherapy Dose on Outcome in Previously Irradiated Recurrent Squamous Cell Carcinoma of the Head and Neck Treated With Stereotactic Body Radiation Therapy”.Am J Clin Oncol 2011; 34(4): 372-379
  83. Argiris, M. Ghebremichael, B. Burtness, R. Axelrod, R. Conti, A. Forastiere. “A phase II trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a trial of the Eastern Cooperative Oncology Group (E1303)”. Cancer 2011;117(15):3374-82
  84. Argiris, M.V. Karamouzis, R. Smith, A. Kotsakis, M.K. Gibson, S.Y. Lai, S. Kim, B.F. Branstetter, Y. Shuai, M. Romkes, L. Wang, J.R. Grandis, R.L. Ferris, J.T. Johnson, D.E. Heron. “Phase I trial of pemetrexed in combination with cetuximab and concurrent radiotherapy in patients with head and neck cancer”Annals of Oncology 2011;22:2482-8
  85. Argiris, M.V. Karamouzis, W.E. Gooding, B.F. Branstetter, S. Zhong, L.E. Raez, P. Savvides, M. Romkes. “Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer” J Clin Oncology 2011;29:1140-45
  86. Argiris. “Editorial-Emerging Concepts in the Treatment of Advanced Non-Small Cell Lung Cancer”The Open Lung Cancer Journal [DOI:10.2174/1876819901003010045] Pp 45
  87. G. Mountzios, T. Owonikoko, M. Karamouzis and A. Argiris. “Current and Emerging Roles of Epidermal Growth Factor Receptor Inhibitors in Advanced Non-Small Cell Lung Cancer”The Open Lung Cancer Journal [DOI: 10.2174/1876819901003010057] Pp 57-65
  88. A.A. Tarhini, A. Argiris.“Maintenance Therapy for Advanced-Non Small Cell Lung Cancer”The Open Lung Cancer Journal [DOI: 10.2174/1876819901003010073]Pp 73-75
  89. T.M. Feinstein, S.Y. Lai, D. Lenzner, W. Gooding, R.L. Ferris, J. R. Grandis, E.N. Myers, J.T. Johnson, D.E. Heron, A. Argiris.“Prognostic factors in patients with high-risk, locally advanced salivary gland cancers treated with surgery and postoperative radiotherapy”Head and Neck 2011;33:318-23
  90. Kotsakis,A. Argiris. “A phase II study of bortezomib in combination with doxorubicin in recurrent or metastatic adenoid cystic carcinoma of the head and neck”Forum of Clinical Oncology 2011; 2(2)
  91. Argiris, S.C. Lee, T. Feinstein, B. F. Branstetter, W.E. Gooding, R.L. Ferris.“Serum biomarkers as potential predictors of antitumor activity of cetuximab-containing therapy for locally advanced head and neck cancer”Oral Oncology 2011;47: 961-6
  92. M.Q. Baggstrom, Y. Qi, M. Koczywas, A. Argiris, E.A. Johnson, M.J. Millward, C. Erlichman, C.M. Rudin, R. Govindan. “A phase II study of AT-101 (gossypol) in chemotherapy-sensitive recurrent extensive stage small cell lung cancer”Journal of Thoracic Oncology 2011; 6(10): 1757-1760
  93. N.E. Bhola, S.M. Thomas, M. Freilino, S. Joyce, A. Sahu, J. Maxwell, A. Argiris,R. Seethala, J.R. Grandis. “Targeting GPCR-mediated p70S6K activity may improve head and neck cancer response to cetuximab” Clinical Cancer Research 2011;17(15):4996-5004
  94. Argiris, A. G. Duffy, S. Kummar, N. L. Simone, M., Y. Arai, S. F. Rudy, V. Kannabiren, X. Yang, M. Jang, Z. Chen, T. Cooley-Zgela, S.G. Ramanand, A. Ahsan, M. K. Nyati, J.J. Wright, C. Van Waes. “Early tumor progression associated with enhanced EGFR signaling with bortezomib, cetuximab, and radiotherapy for head and neck cancer”Clinical Cancer Research2011;17(17):5755-64
  95. A.Vaezi, X-Z. Wang, S. Buch, W.E. Gooding, L. Wang, R. Seethala, D.T. Weaver, A.D. D’Andrea, A. Argiris, R. Marjorie, L.J. Niedernhofer, J.R. Grandis. “XPF expression and clinical outcome in squamous cell carcinoma of the head and neck”Clinical Cancer Research 2011;17(16):5513-22
  96. A.Argiris, T.M. Feinstein, L. Wang, T. Yang, S. Agrawal, L. Appleman, R. Stoller, J.R. Grandis, A.M. Egloff.“Phase I and pharmacokinetic study of dasatinib and cetuximab in patients with advanced solid malignancies” Investigational New Drugs 2012; 30(4):1575-84
  97. R.S Mehta, D. Lenzer, A. Argiris. “Race and health disparities in patient refusal of surgery for early stage non-small cell lung cancer: a SEER cohort study”Annals of Surgical Oncology 2012;19(3):722-7
  98. B.J. Gitlitz, D.D. Tsao-Wei, S. Groshen , A. Davies, M. Koczywas, C.P. Belani , A. Argiris, S. Ramalingam, E.E. Vokes, M. Edelman, P. Hoffman, M.S. Ballas, S.V. Liu, D.R. Gandara. “APhase II Study of Halichondrin B Analog Eribulin Mesylate (E7389) in Patients with Advanced Non-small Cell Lung Cancer Previously Treated with a Taxane: A CaliforniaCancer Consortium Trial”J Thorac Oncol 2012; 7: 574-578
  99. S.E. Wheeler, D.R. Siwak, R. Chai, C. LaValle, R.R. Seethala, Lin Wang, K. Cieply, C. Sherer, C. Joy, G. B. Mills, A. Argiris, J.M. Siegfried, J.R. Grandis, A.M. Egloff. “Tumor epidermal growth factor receptor (EGFR) and EGFR PY1068 are independent prognostic indicators for head and neck squamous cell carcinoma”Clinical Cancer Research 2012; 18: 2278-2289
  100. Kotsakis, M. Harasymczuk, Bastian Schilling, V. Georgoulias, A. Argiris, T. Whiteside. “Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples”.Journal of Immunological Methods 2012; 381:14-22.
  101. Howard S. Moskowitz, William E. Gooding, Sufi M. Thomas, Maria L. Freilino, Neil Gross, Athanassios Argiris, Jennifer R. Grandis, Robert L. Ferris. "Serum Biomarker Modulation Following Molecular Targeting of Epidermal Growth Factor and Cycloxygenase Pathways: a Pilot Randomized Trial in Head and Neck Cancer". Oral Oncology 2012; 48(11):1136-1145
  102. J. Gilbert, JW Lee, A. Argiris, M. Haigentz, L.E. Feldman, M. Jang, P. Arun, C. Van Waes, A.A. Forastiere.“Phase II Two Arm Trial of the Proteasome Inhibitor, PS-341 (VELCADE) in Combination with Irinotecan or PS-341 Alone Followed by the Addition of Irinotecan at Time of Progression in Patients with Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) (E1304): A trial of the Eastern Cooperative Oncology Group”. Head and Neck 2013;35:942-8
  103. Argiris, A.P. Kotsakis, T. Hoang, F.P. Worden, P. Savvides, M.K. Gibson, W. Gooding, G.R. Blumenschein Jr., H.X. Chen, J.R. Grandis, P.M. Harari, M.S. Kies, S. Kim. “Cetuximab and bevacizumab: preclinical data and phase II trial in patients with recurrent or metastatic head and neck cancer”Ann Oncol 2013 Jan;24(1):220-5
  104. A. Argiris, M. Ghebremichael, J. Gilbert, J. Lee, K. Sachidanandam, J. M. Kolesar, B. Burtness, A. A. Forastiere. “Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial”J Clin Oncol. 2013 Apr 10;31(11):1405-14
  105. A. Argiris, E .Pennella, A. Koustenis, A. M. Hossain, C. K. Obasaju. “Pemetrexed in head and neck cancer: A systematic review” Oral Oncol. 2013 Jun;49(6):492-501
  106. Ramalingam SS, Kotsakis A, Tarhini AA, Heron, D. E., Smith, R., Friedland, D., Petro, D. P., Raez, L. E., Brahmer, J. R., Greenberger, J. S., Dacic, S.,Hershberger, P., Landreneau, R. J., Luketich, J. D., Belani, C. P., Argiris, A.“A multicenter phase II study of cetuximab in combination with chest radiotherapy and consolidation chemotherapy in patients with stage III non-small cell lung cancer”. Lung Cancer 2013;81(3):416-21
  107. Argiris.“Current status and future directions in induction chemotherapy for head and neck cancer”Crit Rev Oncol Hematol. 2013 Oct; 88(1):57-74
  108. Tarhini A., Zahoor, H., McLaughlin, B., Gooding, W.E., Schmitz, J.C., Siegfried, J.M., Socinski, M.A, Argiris, A. “Phase I trial of carboplatin and etoposide in combination with panobinostat in patients with lung cancer”.Anticancer Research 2013;10:4475-84
  109. Argiris, S. Lu, M. Ghebremichael, A.M. Egloff, L. Wang, A.A. Forastiere, B.A. Burtness, R. Mehra. “Prognostic significance of human papillomavirus in recurrent or metastatic head and neck cancer: an analysis of Eastern Cooperative Oncology Group trials”Annals of Oncology 2014;24:1410-16
  110. N.D. Gross, J.E.Bauman, W.E.Gooding,W.H. Denq, S.M.Thomas, L.Wang, S.Chiosea, B.L.Hood, M.S. Flint, M.Sun, T.P.Conrads, R.L.Ferris, J.T. Johnson, S. Kim, A. Argiris, L.J.Wirth, M.N.Nikiforova, J.M.Siegfried,JR.N.D. Grandis.“Erlotinib, erlotinib-sulindac vs. placebo: a randomized, double-blind, placebo-controlled window trial in operable head and neck cancer” Clin Cancer Res 2014;20:3289-98
  111. P.J. Schuler,M. Harasymczuk, C.Visus, A.Deleo, S.Trivedi, Y.Lei, A. Argiris,W.Gooding, L.H.Butterfield, T.L.Whiteside, R.L. Ferris.“Phase I Dendritic Cell p53 Peptide Vaccine for Head and Neck Cancer”Clin Cancer Res 2014;20(9):2433-44
  112. D.M.Posluszny, A.L.Dougall, J.T.Johnson, A .Argiris, R.L.Ferris, A.Baum, D.H. Bovbjerg, M.A.Dew.“Posttraumatic stress disorder (PTSD) symptoms in newly diagnosed head and neck cancer patients and their partners”Head and Neck 2015;37:1282-9
  113. A.M. Egloff, J. Lee, C.J. Langer, J. Lee, H. Quon, A Vaezi, J.R. Grandis, R. Seethala, L. Wang, D.M. Shin,A. Argiris, D. Yang, R. Mehra, J.A. Ridge, U.A. Patel, B.A. Burtness, A.A. Forastiere. “Phase II Study ofCetuximab in Combination with Cisplatin and Definitive Radiation in Unresectable, Locally Advanced Squamous Cell Carcinoma of the Head and Neck: Eastern Cooperative Oncology Group Trial E3303”Clin Cancer Res 2014;20:5041-51
  114. Butts C, Socinski MA, Mitchell PL, Thatcher N, Havel L, Krzakowski M, Nawrocki S, Ciuleanu TE, Bosquée L, Trigo JM, Spira A, Tremblay L, Nyman J, Ramlau R, Wickart-Johansson G, Ellis P, Gladkov O, Pereira JR, Eberhardt WE, Helwig C, Schröder A, Shepherd FA; START trial team. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2014 Jan;15(1):59-68. doi: 10.1016/S1470-2045(13)70510-2
  115. M.Yao, N. Galanopoulos, P. Lavertu, P. Fu, M. Gibson, A. Argiris, R. Rezaee, C. Zender, J. Wasman, M. Machtay, P. Savvides. “Phase II Study of Bevacizumab inCombination with Docetaxel and Radiation in Locally Advanced Squamous Cell Carcinoma of the Head and Neck” Head and Neck 2015;37:1665-72
  116. M. Vasilakopoulou, A. Psyrri, A. Argiris. “Targeting angiogenesis in head and neck cancer”.Oral Oncology 2015;51:409-15
  117.  Argiris.“EGFR inhibition for recurrent and/or metastatic HNSCC” Lancet Oncol 2015;16:488-9
  118. H-B Jie, P.J. Schuller, S.C. Lee, R.M. Srivastava,A. Argiris, S. Ferrone, T.L. Whiteside, R.L. Ferris. “CTLA-4+ Regulatory T Cells are Increased in Cetuximab Treated Head and Neck Cancer Patients, Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis” Cancer Res 2015;75:2200-10
  119. C.S. Ha, J. Michalek, R. Elledge, K.R. Kelly, S. Ganapathy, H. Su, C.A. Jenkins, A. Argiris, R. Swords, T.Y. Eng, A. Karnad, R.L. Crownover, G.P. Swanson, M. Goros, B.H. Pollock, Z-M. Yuan. “P53-based Strategy to Reduce Hematological Toxicity of Chemotherapy: A Proof of Principle Study”. Molecular Oncology 2015
  120. Soria JC, Felip E, Cobo M, Lu S, Syrigos K, Lee KH, Göker E, Georgoulias V, Li W, Isla D, Guclu SZ, Morabito A, Min YJ, Ardizzoni A, Gadgeel SM, Wang B, Chand VK, Goss GD; LUX-Lung 8 Investigators. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2015 Aug;16(8):897-907. doi: 10.1016/S1470-2045(15)00006-6
  121. S.J. Wong, T. Karrison, D.N. Hayes, M.S Kies, K.J. Cullen, T. Tanvetyanon, A. Argiris, N. Takebe, D. Lim, N.F. Saba, F.P. Worden, J. Gilbert, H.J. Lenz, A.R. Razak, J.D. Roberts, E.E. Vokes, E.E. Cohen.“Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for non-adenoid cystic malignant salivary gland tumors”.Ann Oncol 2016;27:318-23
  122. A.Argiris, A.D. Rapidis. “Postoperative treatment for head and neck cancer: the emerging role of EGFR-targeted therapy”. Translational Cancer Research 2016
  123. K.A. Lang Kuhs, M. Pawlita, Sumita Trivedi, S.P. Gibson, N.C. Schmitt, A. Argiris, A.R. Kreimer, R.L. Ferris, T. Waterboer. “Characterization of human papillomavirus antibodies in individuals with head and neck cancer”Cancer Epidemiology2016
  124. Z. Piperigkou, K. Karamanou, A.B. Engin, C. Gialeli, D. Nikitovic, D.H. Vynios, M.S.G. Pavão, K.S. Golokhvast, M.I. Shtilman, A. Argiris, A.M. Tsatsakis.“Emerging aspects of nanotoxicology in health and disease: from agriculture and food sector to cancer therapeutics”. Food and Chemical Toxicology 2016;91:42-57
  125. Argiris, J.E. Bauman, J. Ohr, W. Gooding, D.E. Heron, U. Duvvuri, G.J. Kubicek, D.M. Posluszny, M. Vassilakopoulou, S. Kim, J.R. Grandis, J.T. Johnson, M.K. Gibson, D. A. Clump, J.T. Flaherty, S.I. Chiosea, B. Branstetter, R.L. Ferris. “Phase II randomized trial of radiation therapy, cetuximab and pemetrexed with or without bevacizumab in patients with locally advanced head and neck cancer”Annals of Oncology 2016;27:1594-600
  126. J.L. Geiger, J.E. Bauman, M.K. Gibson, W.E. Gooding, P. Varadarajan, A. Kotsakis, D. Martin, J.S. Gutkind, M.L. Hedberg, J.R. Grandis, A. Argiris.“Phase II trial of everolimus in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma” Head and Neck 2016;8:1759-1764
  127. Ferris RL, Geiger JL, Trivedi S, Schmitt NC, Heron DE, Johnson JT, Kim S, Duvvuri U, Clump DA, Bauman JE, Ohr JP, Gooding WE, Argiris A. “Phase II trial of post-operative radiotherapy with concurrent cisplatin plus panitumumab in patients with high-risk, resected head and neck cancer”. Ann Oncol 2016 Oct 11[Epub ahead of print]
  128. Jimeno A, Posner MR, Wirth LJ, Saba NF, Cohen RB, Popa EC, Argiris A, Grossmann KF, Sukari A, Wilson D, Zhang X, Sun J, Glasser C, Attie KM, Sherman ML, Pandya SS, Weiss J. “A phase 2 study of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck”. Cancer 2016 Dec 1;122:3641-3649
  129. Ou SI, Govindan R, Eaton KD, Otterson GA, Gutierrez ME, Mita AC, Argiris A, Brega NM, Usari T, Tan W, Ho SN, Robert F. “Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer”. J Thorac Oncol. 2017 Jan;12(1):145-151.
  130. Jie HB, Srivastava RM, Argiris A, Bauman JE, Kane LP, Ferris RL. Increased PD-1+ and TIM-3+ TILs during Cetuximab Therapy Inversely Correlate with Response in Head and Neck Cancer Patients. Cancer Immunol Res. 2017 May;5(5):408-416.
  131. Argiris A, Harrington KJ, Tahara M, Schulten J, Chomette P, Ferreira Castro A, Licitra L. Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck. Front Oncol. 2017 May 9;7:72.
  132. Tarhini AA, Rafique I, Floros T, Tran P, Gooding WE, Villaruz LC, Burns TF, Friedland DM, Petro DP, Farooqui M, Gomez-Garcia J, Gaither-Davis A, Dacic S, Argiris A, Socinski MA, Stabile LP, Siegfried JM. Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non-small cell lung cancer. Cancer. 2017 Aug 1;123(15):2936-2944. 
  133. Argiris A, Lee JW, Stevenson J, Sulecki MG, Hugec V, Choong NW, Saltzman JN, Song W, Hansen RM, Evans TL, Ramalingam SS, Schiller JH. Phase II randomized trial of carboplatin, paclitaxel, bevacizumab with or without cixutumumab (IMC-A12) in patients with advanced non-squamous, non-small-cell lung cancer: a trial of the ECOG-ACRIN Cancer Research Group (E3508). Ann Oncol. 2017 Dec 1;28(12):3037-3043.
  134. Garas G, Markar SR, Malietzis G, Ashrafian H, Hanna GB, Zacharakis E, Jiao LR, Argiris A, Darzi A, Athanasiou T. Induced Bias Due to Crossover Within Randomized Controlled Trials in Surgical Oncology: A Meta-regression Analysis of Minimally Invasive versus Open Surgery for the Treatment of Gastrointestinal Cancer.  Ann Surg Oncol. 2018 Jan;25(1):221-230.